Synthesis and evaluation of non-basic inhibitors of urokinase-type plasminogen activator (uPA)

被引：14

作者：

Venkatraj, Muthusamy ^{[1
]}

Messagie, Jonas ^{[1
]}

Joossens, Jurgen ^{[1
]}

Lambeir, Anne-Marie ^{[2
]}

Haemers, Achiel ^{[1
]}

Van der Veken, Pieter ^{[1
]}

Augustyns, Koen ^{[1
]}

机构：

[1] Univ Antwerp, Med Chem Lab, B-2610 Antwerp, Belgium

[2] Univ Antwerp, Med Biochem Lab, B-2610 Antwerp, Belgium

来源：

BIOORGANIC & MEDICINAL CHEMISTRY | 2012年 / 20卷 / 04期

关键词：

Naphthamides; Naphthalene sulfonamides; Urokinase inhibitors; uPA; tPA; SELECTIVE INHIBITORS; FACTOR XA; SYSTEM; CANCER; POTENT; IDENTIFICATION; DERIVATIVES; METASTASIS; REDUCTION; DISCOVERY;

D O I：

10.1016/j.bmc.2011.12.040

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Recent drug discovery programs targeting urokinase plasminogen activator (uPA) have resulted in non-peptidic inhibitors consisting of amidine or guanidine functional groups attached to aromatic or heteroaromatic scaffolds. There is a general problem of poor oral bioavailability of these charged inhibitors. In this paper, we report the synthesis and evaluation of a series of naphthamide and naphthalene sulfonamides as uPA inhibitors containing non-basic groups as substitute for amidine or guanidine groups. (C) 2012 Elsevier Ltd. All rights reserved.

引用

页码：1557 / 1568

页数：12

共 50 条

[21] Expression of Urokinase-type Plasminogen Activator (uPA), uPA Receptor, and Plasminogen Activator Inhibitor-1 in Oral Squamous Cell Carcinoma
Inoue, Yoshiko
Sugiura, Tsuyoshi
VIatsuki, Ryousuke
Ishii, Kotaro
Seki, Katsuhiro
Shirasuna, Kanemitsu
ORAL SCIENCE INTERNATIONAL, 2007, 4 (01) : 38 - 44
[22] Cancer treatment with inhibitors of urokinase-type plasminogen activator and plasmin
Dunbar, SD
Ornstein, DL
Zacharski, LR
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2000, 9 (09) : 2085 - 2092
[23] Prognostic relevance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in gastric cancer
Ito, H
Yonemura, Y
Fujita, H
Tsuchihara, K
Kawamura, T
Nojima, N
Fujimura, T
Nose, H
Endo, Y
Sasaki, T
VIRCHOWS ARCHIV, 1996, 427 (05) : 487 - 496
[24] Autoactivation of avian urokinase-type plasminogen activator (uPA) - A novel mode of initiation of the uPA/plasmin cascade
Alexander, DS
Sipley, JD
Quigley, JP
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (13) : 7457 - 7461
[25] Evaluation of plasma urokinase-type plasminogen activator and urokinase-type plasminogen-activator receptor in patients with acute and chronic hepatitis B
Zhou, Huanqin
Wu, Xianguo
Lu, Xingguo
Chen, Gang
Ye, Xiongwei
Huang, Jian
THROMBOSIS RESEARCH, 2009, 123 (03) : 537 - 542
[26] QSAR study of substituted 2-pyridinyl guanidines as selective urokinase-type plasminogen activator (uPA) inhibitors
Karthikeyan, C.
Moorthy, N. S. Hari Narayana
Trivedi, Piyush
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2009, 24 (01) : 6 - 13
[27] Soluble urokinase-type plasminogen activator receptor and urokinase-type plasminogen activator receptor contribute to chemoresistance in leukemia
Guo, Hong
Zhou, Lan-Xia
Ma, Haizhen
Liu, Bei
Cheng, Juan
Ma, Yun-Yun
Zhao, Li
ONCOLOGY LETTERS, 2017, 14 (01) : 383 - 389
[28] Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: Correlation with tumor associated macrophage and prognosis
Ohba, K
Miyata, Y
Kanda, S
Koga, S
Hayashi, T
Kanetake, H
JOURNAL OF UROLOGY, 2005, 174 (02): : 461 - 465
[29] Effect of Plasmin Cleavage on the Dynamics of the Protease Domain of the Urokinase-Type Plasminogen Activator (uPA)
Torres-Paris, Constanza
Chen, Yueyi
Komives, Elizabeth A.
BIOPHYSICAL JOURNAL, 2019, 116 (03) : 484A - 484A
[30] Circulating levels of urokinase-type plasminogen activator (uPA) in breast and pancreatic cancer patients
Hamer, PJ
Marx, JH
Leitzel, K
Ali, S
Clarke, L
Demers, L
Harvey, HA
Linnartz, R
Lipton, A
Mietlowski, W
Carney, WP
CLINICAL CHEMISTRY, 2005, 51 : A53 - A54

← 1 2 3 4 5 →